SpeeDx Company
%20.jpg)
SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease.
Estimated Revenue:
$1M to $10M
Funding Status:
Early Stage Venture
Industry:
Biotechnology, Health Diagnostics, Medical
Last Funding Date:
2020-02-12
Technology:
diagnostics
Founded Date:
39814
Headquarters:
Sydney, New South Wales, Australia
Last Funding Type:
Series B
Employee Number:
11-50